Dr. Adams to further advance promising pipeline, including breakthrough therapy, NiCord, in phase 3 development as a universal bone marrow transplant solution. Source: BioSpace

PellePharm is aiming to launch Phase III trials of the topical hedgehog inhibitor in early 2018. Source: BioSpace

The approval was based on results from a trial that demonstrated a significant reduction in the risk of a disease-free survival (DFS) event for patients at high risk of RCC…

Bloomberg noted that Takeda's CEO is looking at making Takeda a nimble company, but one with a deeply entrenched R&D focus. Source: BioSpace

Azar, the new HHS nominee, is being pitched as someone who will help lower the price of prescription drugs. Source: BioSpace

This submission allows the FDA to review completed portions of the NDA on an ongoing basis. Alnylam expects to submit final clinical data by year end. Source: BioSpace

The company's common stock will begin trading on the Nasdaq under the ticker symbol "SCPH" today. Source: BioSpace

The FDA has assigned a new Prescription Drug User Fee Act goal date of May 8, 2018. Source: BioSpace

Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. Source: BioSpace

Celgene loves cozying up to emerging biotech stocks working on next-generation medicine, and one of those collaborations is with Jounce Therapeutics. Source: BioSpace